Edwards Lifesciences Corporation
—- Market cap
- $50.01B
- Debt
- —
- Cash
- −$2.94B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EW stock price vs MDT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MDT's multiple
Needs MDT P/E.
Implied fair value · at EW's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Medtronic plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe Edwards can stabilize and reverse revenue decline (current Revenue Growth -9.4%) while maintaining its superior margins and ROIC, then initiate or add to a long position because the stock trades at $81.36 versus a MDT-implied P/E price of $198.79 (144.3% upside) and benefits from high margins, strong ROIC (19.1%) and low leverage (Debt/Equity 0.1x).
MDT-implied P/E valuation implies a large upside (implied price $198.79 vs current $81.36, +144.3%), driven primarily by Edwards' much lower P/E (11.7x) relative to Medtronic (28.5x). However, on a P/S basis Edwards is actually richer (8.8x vs 3.9x), so valuation conclusions depend on whether investors prioritize earnings or sales multiples. The current price sits inside the historical band ($73.22 - $89.50) near the lower end, suggesting limited historical downside from here.
Supporting Metrics